Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03799666
Other study ID # SAICT-POL/23926/2016
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 7, 2019
Est. completion date June 30, 2020

Study information

Verified date July 2020
Source Aveiro University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

3R aims to increase the access of patients with chronic respiratory diseases (CRD) to pulmonary rehabilitation (PR) in Portugal. The main goals of 3R are: i) design and implement an innovative community-based PR programme; ii) assess the cost-benefit of the community-based PR programme; iii) disseminate and perform knowledge transfer about PR across the country.

PR is an evidence-based intervention for the management of CRD and offering PR has been defined as a priority by national/international organizations. However, in Portugal PR is practically inexistent (<1% of "candidate" patients have access). Currently, PR programmes are hospital-based and directed to patients with advanced disease. One of the recommendations to enhance the implementation of PR is the development on novel models of programme delivery. It is hypothesised that community-based programs, direct to patients at all grades of the disease, and involving all stakeholders (health professionals, patients, society, policy makers) may turn PR more accessible.

The plan is to implement community-based PR programs in 4 primary care centres of 2 ACES of the centre region of Portugal and assess the impact of such intervention in several domains using surrogate and patient-/family-centered outcomes. A cost-benefit analysis will be performed on acute exacerbations and healthcare utilization. Dissemination will include one conference, activities with the community, courses and an online PR toolkit. Four schools of 2 polytechnics, 2 city councils, the Health Regional Administration-Centre (ARS-Centro) and all respiratory professional and civic national associations are partners.


Description:

More than 1 billion people suffer from chronic respiratory diseases worldwide and, in Europe, the total annual cost of respiratory diseases amounts to more than €380 billion. In Portugal, respiratory diseases are the 3rd leading cause of death and direct costs related to hospitalizations (in 2013 - €213 millions). Management of chronic respiratory diseases are high priorities for the National Health Service, and particularly, for the Center Health Regional Administration.

Pulmonary rehabilitation (PR) is an evidence-based intervention for the management of patients with chronic respiratory diseases (grade A). Offering PR has long been defined as a priority by several national and international organizations. Despite this firm recommendation and the knowhow on the provision of PR, in Portugal, PR is practically inexistent, with <1% of "candidate" patients having access to this standard care. Therefore, the need for a National Network on PR has been acknowledged as a priority.

It is hypothesised that community-based programmes, direct to patients at all grades of the disease, and involving all stakeholders (health professionals, patients/family, society, policy makers) may turn PR more accessible. Thus, the main goal of this project is to increase the access of patients with chronic respiratory diseases, namely COPD, to PR in the center region of Portugal and disseminate this intervention nationally.

3R aims to implement and disseminate community-based PR programs in Portugal. Specifically, it will:

1. Implement 4 community-based PR programmes (Task 1);

2. Create an online platform for clinical storage and analysis of the data collected (Task 2);

3. Perform a cost-benefit analysis of the implemented PR programmes (Task 3);

4. Create a Portuguese online PR toolkit (Task 4);

5. Promote knowledge transfer about PR (Task 5). The plan is to implement community-based PR programmes in 4 primary care centres of 2 ACES (Baixo Vouga - BV, and Baixo-Mondego - BM) of the centre region and assess the impact of such intervention in several domains. Surrogate and patient/family centered outcome measures will be used. A cost-benefit analysis will be performed on acute exacerbations and healthcare utilization and costs. Finally, dissemination and knowledge transfer of the project will be conducted through: an international conference, activities with the community, three PR courses; the development of the Portuguese online PR toolkit to support the widespread implementation of PR in Portugal and via publications.

To bring PR from bench to Portuguese common practice, 3R brings together a strong consortium composed of 4 schools of 2 Polytechnic Institutions, 2 City Councils, Health Regional Administration - Centre and all respiratory national associations (Sociedade, Portuguesa do Pulmão - SPP, RESPIRA and Fundação Portuguesa do Pulmão - FPP). This consortium involves an experienced team with complementary backgrounds and integrates students from the several institutions during all activities. It is strongly believed that jointly this multidisciplinary team has the experience and complementary skills, as well as the means, to guarantee the success and outreach of the project.

It is estimated that 73 patients will be required to detect significant differences in patients' health-related quality of life (HRQOL), based on a previous study. Stable patients with CRD and their family members will be recruited from Primary Care Centres (PCCs) of the ACES of Baixo Vouga and Baixo Mondego (ACES-BV & BM). Family doctors from PCCs will provide a list of eligible individuals. Individuals/families will be contacted and those interested will meet with researchers to receive further information about the study and sign the informed consents. Participants will be divided in two groups: experimental (EG) and control (CG). The EG will include participants/families wanting to participate in a 12-week community-based PR programme and the CG will include those willing to collaborate in data collection but not in the PR programmes (Task 1). The PR programme will include exercise training (endurance, strength and balance training) twice a week and psychoeducational sessions every two weeks performed by a multidisciplinary team.

Data will be collected at baseline, at 12 weeks (i.e., immediately post-PR), 3 and 6 months post-PR.

Data analysis will be undertaken using Statistical Package for the Social Sciences (SPSS) software and will include descriptive and inferential statistics. To analyse changes in outcome measures, data from baseline and after treatment assessments will be compared. Moreover, between groups comparisons will also be performed for baseline, after intervention and follow-ups assessments. Effect sizes for the interventions will also be calculated.


Recruitment information / eligibility

Status Completed
Enrollment 146
Est. completion date June 30, 2020
Est. primary completion date December 30, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- clinical diagnosis of a chronic respiratory disease

- clinically stable in the previous month

- = 18 years old

- able to provide their own informed consent

Exclusion Criteria:

- cognitive impairments

- inability to understand and co-operate

- history of neoplasic /immunologic disease or acute cardiac condition or a significant cardiac, musculoskeletal, neuromuscular or psychiatric condition.

Study Design


Intervention

Other:
Pulmonary Rehabilitation
Patients will be treated with daily medication prescribed by the physician. Additionally patients will participate in a 12-w.eek community-based pulmonary rehabilitation programme, with two exercise training sessions per week and six psycho-education sessions, managed by a multidisciplinary team, once every two weeks. Patient's families will be invited to participate in the psychoeducational component
Daily medication
Patients will be treated with daily medication prescribed by the physician and will continue to receive the standard care from the primary care centre team.

Locations

Country Name City State
Portugal University of Aveiro Aveiro

Sponsors (2)

Lead Sponsor Collaborator
Aveiro University Fundação para a Ciência e a Tecnologia

Country where clinical trial is conducted

Portugal, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in Body Mass Index Patients' body mass index will be assessed in kg/m^2 based on patients' height and weight. Up to 9 months
Primary Change in Health Related quality-of-life: St. George Respiratory Questionnaire St. George Respiratory Questionnaire (SGRQ) will be used to assess Health Related quality-of-life. The SGRQ is a comprehensive well-established 50-item questionnaire to measure health status in patients with chronic respiratory diseases. Scores can be provided for each domain and as a total score, ranging from 0 (no impairment) to 100 (worst possible health status). Up to 9 months
Secondary Change in airflow obstruction Forced expiratory volume in one second and forced vital capacity will be measured with a portable spirometer to assess the degree of airflow obstruction. Results will be expressed in liters and percentage of predicted. We will calculate the ratio between the forced expiratory volume in one second and the forced vital capacity. Up to 9 months
Secondary Change in exercise capacity Exercise capacity will be tested in a 6-minute walk test, since it allows exercise prescription. The test results will be presented as the walked distance (meters). Up to 9 months
Secondary Change in functionality Functionality will be tested with the 1-minute sit-to-stand, with the results presented as number of sit-to-stand repetitions. Up to 9 months
Secondary Change in quadriceps muscle strength Quadriceps muscle strength will be measured using a handheld dynamometer (kilogram/force). Up to 9 months
Secondary Change in biceps muscle strength Biceps muscle strength will be measured using a handheld dynamometer (kilogram/force). Up to 3 months
Secondary Change in muscle cross sectional area Cross-sectional will be measured with ultrasound of the lower (quadriceps) and upper (biceps) limb muscles. Up to 3 months
Secondary Change in upper limb muscle strength Upper limb strength will be measured with Handgrip (kg) Up to 9 months
Secondary Change in respiratory muscle strength Respiratory muscle strength will be measured through a respiratory pressure meter to assess inspiratory and expiratory muscle strength (cm/H20) Up to 3 months
Secondary Change in frequency of exacerbations Number of exacerbations in the previous year, healthcare utilization, such as emergency department visits or hospital admissions, in the previous year, which are related to COPD decline Up to 9 months
Secondary Change in Healthcare utilization Healthcare utilization will be assessed through the number of participants that visit emergency department and the number of visits of each participant in the previous year. The number and duration of hospital admissions in the previous year will also be assessed. Up to 9 months
Secondary Change in family adaptability/cohesion Family function was assessed with the family adaptability and cohesion evaluation scale (FACES-IV). The FACES-IV is a 62 items subdivided in: cohesion and flexibility dimensions, and family communication and family satisfaction scales. The cohesion and flexibility dimensions provide six family scales, two balanced scales (Balanced cohesion and balanced flexibility, with percentile scores ranging from 16 to 85) and four unbalanced scales (Disengaged, Enmeshed, Rigid and Chaotic, with percentile scores ranging from 10 to 99). The six family types (Balanced, Rigidly Cohesive, Midrange, Flexibly unbalanced, chaotically unbalanced and unbalanced) can be plotted onto the Circumplex Model. The family communications and Satisfaction scales are composed of 10 items each, with percentile scores ranging from 10 to 99. In all FACES-IV subscales higher scores indicate better family cohesion, flexibility, communication or satisfaction. Up to 3 months
Secondary Change in balance Balance will be assessed with the Brief-Best tests. Up to 3 months
Secondary Change in Physical activity Accelerometry will be used to assess physical activity. Up to 3 months
Secondary Change in Physical activity The Brief Physical Activity questionnaire will be used to assess physical activity. It a 2 items questionnaire, with scores ranging from 0 to 8. If the sum of the two items score is above or equal 4 the subject will be considered physically active. Up to 9 months
Secondary Change in Diaphragm excursion Ultrasound will be used to assess the diaphragm excursion, only volunteer from patients who agree to come to ESSUA and will be seen previously by a physician Up to 3 months
Secondary Change in Dyspnoea Medical Research Council scale will be used to assess functional dyspnoea related to respiratory impairment. It is a 5-point scale, rated from 0 to 4, with higher scores denoting greater breathlessness severity. Up to 9 months
Secondary Change in symptom's impact in patients life COPD Assessment Test (CAT) will be used to assess burdensome symptoms in patients' life with 8 items (cough, sputum, dyspnoea, chest tightness, capacity of exercise and home daily activities, confidence leaving home, sleep and energy levels).he scores range from 0-40, organised in 4 categories, namely <10 low impact, 10-20 medium, 21-30 high and >30 very high impact, with 5 representing the upper limit of normal in healthy non-smokers Up to 9 months
Secondary Change in Emotional state Hospital Anxiety and Depression Scale will be used to assess symptoms of anxiety and depression. It is a 14 item questionnaire that can be subdivided in two subscales: anxiety and depression. Scores are provided for each subscale and range from 0 to 21, with higher scores meaning more symptoms of anxiety and depression. Up to 9 months
Secondary Change in Fatigue symptoms The fatigue subscale of the Checklist of Individual Strength (CIS-20) will be used to assess fatigue.The subscale of subjective fatigue is a 8-item questionnaire, with higher scores indicating higher levels of fatigue. The total scores range from 8 to 56. Up to 3 months
Secondary Change in Fatigue The Functional Assessment of Cancer Therapy - Fatigue subscale (FACIT-F) will be used to assess fatigue levels. It is multi-dimensional 13-item questionnaire assessing tiredness, weakness and difficulty in handling daily activities due to fatigue. Scores range from 0 to 52, with higher scores indicating less fatigue. Up to 3 months
Secondary Change in cough-related quality of life: Leicester Cough Questionnaire Cough-related quality of life will be assessed with the Leicester Cough Questionnaire, which is a 19 items scale organised in 3 domains (physical, psychological and social). Each domain has a score ranging from 1 to 7 and the LCQ total score varies from 3 to 21. Higher scores express a better quality of life and less impact of cough. Up to 3 months
Secondary Change in cough and sputum symptoms The Cough and Sputum Assessment Questionnaire (CASA-Q) will be used to assess cough and sputum symptoms, based on their reported frequency and severity, and their impact on daily activities. t is a 20-item questionnaire containing 4 domains: cough symptoms, cough impact, sputum symptoms and sputum impact. All items are rescored and summed, achieving a score ranging from 0 to 100 for each domain, with higher scores indicating fewer symptoms or less cough and sputum impact. Up to 3 months
Secondary Digital Technology access A survey asking about the use of internet and access to computers, smartphones (combination of mobile phone, web browser and computer capabilities)/tablets and cell phones (simple devices mainly for voice calls and text messages) will be used to assess digital technology access. Confidence in using these technologies will be assessed using a numerical scale from 0 (not at all confident) to 10 (completely confident). At baseline
See also
  Status Clinical Trial Phase
Completed NCT02894190 - Development and Validation of the BVQ
Recruiting NCT04566523 - TeleRehabilitation for Patients With Chronic Respiratory Failure.
Recruiting NCT04139356 - The Effect of Spontaneous Respiration on Pulse-oximetry Measurements N/A
Completed NCT03880630 - Inspiratory Muscle Activation Pattern Analysis in Assisting Precision in Inspiratory Muscle Training in Patients With Chronic Respiratory Disease N/A
Completed NCT03728595 - Validation of a Predictive Score for HAST
Completed NCT03294057 - Collaborative Care With Smart Health Management Program for Patients With Chronic Illness N/A
Completed NCT03704935 - Long Term Effects and of a Pulmonary Rehabilitation Maintenance Program
Recruiting NCT05064605 - Pharmacological Evaluation of Antifungal in Chronic Pulmonary Aspergillosis
Recruiting NCT06149494 - RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection Phase 2
Recruiting NCT03797183 - Genesis Electrical Impedance Tomography (EIT): A Preliminary Study
Enrolling by invitation NCT05724082 - The Effect of Household Air Pollution on Lung Function Growth in Infants With Pneumonia in Sub-Saharan Africa N/A
Completed NCT04623762 - Yoga On Dyspnea, Sleep And Fatıgue In Chronıc Respıratory Dıseases N/A
Not yet recruiting NCT06321471 - AeviceMD for Pediatric Asthma Management N/A
Not yet recruiting NCT06459011 - Shedding Light on a Forgotten Workforce: Loved Ones of People With Chronic Respiratory Diseases
Recruiting NCT05248412 - The Long-term Spill-over Impact of COVID-19 on Health and Healthcare of People With Non-communicable Diseases
Not yet recruiting NCT04911764 - Three-min Step Test and Exercise Desaturation Detection in Chronic Respiratory Insufficiency Patients N/A
Completed NCT02715219 - The Effect of an AEP on Patient's Knowledge Regarding Asthma Disease and Inhaler Technique: RCT N/A
Completed NCT03188588 - Observance of Long Term Oxygen Therapy in Chronic Inspiratory Disease Patients
Completed NCT03930511 - Telemonitoring Physical Activity in Daily Life on Chronic Respiratory Patients N/A
Completed NCT04373070 - Quality-of-Life Management for COPD Patients N/A